The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

GSK is moving out of its 635K SF footprint at 14200 Shady Grove Road, where it is the sole tenant, just before its lease ...

as GSK can deliver here. We're building a portfolio of novel pipeline ADCs with the ability to target tumor cells, while sparing healthy ones. GSK'227 targets B7-H3, an antigen, which is ...

A task force has been set up to look into how to spend a £2m GSK legacy as the pharmaceutical giant closes its doors in Ulverston. Giles ...

“By exploring precancer biology and building on GSK’s expertise in the science of the immune system, we aim to generate key insights for people at risk of developing cancer.” The partnership ...

“By exploring pre-cancer biology and building on GSK’s expertise in the science of the immune system, we aim to generate key insights for people at risk of developing cancer.” Professor ...

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target ...

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

Sustainability and joint working But Belson notes that building trust must go beyond internal projects and involve external efforts as well. He highlights GSK’s recently announced sustainability ...

"By exploring pre-cancer biology and building on GSK's expertise in the science of the immune system, we aim to generate key insights for people at risk of developing cancer." Professor Irene ...